Project Description


ClexBio creates breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with its proprietary hydrogel technology CLEX. CLEX is the result of more than 7 years of R&D within tissue engineering at NTNU, Harvard University, EPFL, and the University of Birmingham and has been published in internationally recognized scientific journals. By combining lab-on-a-chip, biomaterials, and living human cells, ClexBio aims to solve the biggest bottleneck in organ engineering, namely recreating vasculature, and to be the first company to engineer patient-specific blood vessels for preclinical and clinical applications.

ClexBio’s co-founders Armend G. Håti and Manuel Schweikle have academic and industrial expertise from leading universities and biotechs globally. ClexBio is located in Oslo, Norway, and joined NOME in 2021.

Company details


More companies